Abstract: The present invention relates to a chimeric antigen receptor targeting BCMA and uses thereof, and more particularly, to an antibody targeting BCMA, a chimeric antigen receptor comprising the antibody, and CAR-T cells expressing the chimeric antigen receptor. It was confirmed that the chimeric antigen receptor and the CAR-T cell targeting BCMA prepared in the present invention specifically bound to the antigen (BCMA), and activation of the BCMA-bound CAR-T cells was made. In addition, since it was confirmed that the CAR-T cell of the present invention effectively killed BCMA-expressing cells, the chimeric antigen receptor and the CAR-T cell targeting BCMA of the present invention can be applied for use in preventing or treating diseases related to B cell expression or BCMA expression.

Abstract: An antibody specifically binding to BCMA (B-cell maturation antigen) or fragment thereof, including: a heavy chain variable region including a CDR1 region represented by the amino acid sequence of SEQ ID NO: 1, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 2, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 3; and a light chain variable region including a CDR1 region represented by the amino acid sequence of SEQ ID NO: 4, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 5, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 6.

Abstract: An antibody specifically binding to BCMA (B-cell maturation antigen) or fragment thereof, including: a heavy chain variable region including a CDR1 region represented by the amino acid sequence of SEQ ID NO: 1, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 2, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 3; and a light chain variable region including a CDR1 region represented by the amino acid sequence of SEQ ID NO: 4, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 5, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 6.

Abstract: The present invention relates to a composition for diagnosing lung cancer including a preparation capable of measuring expression levels of lung cancer-specific biomarkers SAA, OPN, and CEA at the same time, a kit for diagnosing lung cancer including the same, and a method of diagnosing lung cancer using the composition. The composition for diagnosing lung cancer has effects such as enhanced sensitivity and specificity as compared to conventional biomarkers, thereby exhibiting high diagnostic efficiency.